Implications of Contact Days in the Treatment of Relapsed Refractory Diffuse Large B-Cell Lymphoma

被引：0
|
作者：
Bojanini, Leyla [1 ]
Gupta, Neel [1 ]
Khaki, Ali Raza [1 ,2 ]
机构：
[1] Stanford Univ, Dept Med, Div Oncol, Stanford, CA USA
[2] Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA
来源：
ONCOLOGIST | 2023年 / 28卷 / 09期
关键词：
D O I：
10.1093/oncolo/oyad204
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：750 / 751
页数：2
相关论文
共 50 条
  • [21] FDA Approves Monjuvi for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    不详
    AMERICAN HEALTH AND DRUG BENEFITS, 2020, 13 (05): : 214 - 214
  • [22] Efficacy of Salvage Radiotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Wang, S.
    Chen, J. Y.
    Cao, W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E471 - E472
  • [23] Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma
    Graf, Solomon A.
    Cassaday, Ryan D.
    Morris, Karolyn
    Voutsinas, Jenna M.
    Wu, Qian Vicky
    Behnia, Sanaz
    Lynch, Ryan C.
    Krakow, Elizabeth
    Rasmussen, Heather
    Chauncey, Thomas R.
    Kanan, Sandra
    Soma, Lorinda
    Smith, Stephen D.
    Gopal, Ajay K.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (03): : 176 - 181
  • [24] Efficacy of salvage radiotherapy for relapsed/refractory diffuse large B-cell lymphoma
    Wang, Shu-Bei
    Chen, Jia-Yi
    Zhao, Wei-Li
    Kirova, Youlia M.
    Cao, Wei-Guo
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (04) : 1019 - 1026
  • [25] Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Shingleton, Jennifer R.
    Dave, Sandeep S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 166 - +
  • [26] Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Barca, Eva Gonzalez
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (23)
  • [27] ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma
    Alderuccio, Juan Pablo
    Sharman, Jeff P.
    BLOOD REVIEWS, 2022, 56
  • [28] Efficacy and safety of lenalidomide in relapsed/refractory diffuse large B-cell lymphoma
    Habermann, T.
    Lossos, I.
    Justice, G.
    Tuscano, J.
    Cole, C.
    Vose, J.
    Pietronigro, D.
    Takeshita, K.
    Ervin-Haynes, A.
    Zeldis, J.
    Wiernik, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 150 - 150
  • [29] Diffuse Large B-Cell Lymphoma: Optimizing Therapy for Relapsed/Refractory Disease
    Matasar, Matthew J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (11.5): : 1327 - 1330
  • [30] The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma
    Rushton, Christopher
    Alcaide, Miguel
    Cheung, Matthew
    Michaud, Neil R.
    Daigle, Scott
    Rys, Ryan N.
    Arthur, Sarah E.
    Zrymiak, Marquisa
    Davidson, Jordan
    Bushell, Kevin R.
    Yu, Stephen
    Jain, Michael D.
    Shepherd, Lois E.
    Marra, Marco A.
    Kuruvilla, John
    Crump, Michael
    Mann, Koren Kathleen
    Assouline, Sarit E.
    Connors, Joseph M.
    Steidl, Christian
    Johnson, Nathalie A.
    Scott, David W.
    Morin, Ryan D.
    BLOOD, 2020, 136
12345